Mucormycosis is an invasive mold infection, frequently fatal in immunocompromised patients. We report the case of a patient with chronic lymphocytic leukemia admitted to the hematology unit for febrile aplasia. Pulmonary lesions suggesting a fungal infection expanded/increased despite a combination of posaconazole and liposomal amphotericin B. The fungal biomarkers performed repeatedly were negative. At D65 after chemotherapy a bronchial biopsy was positive for Cunninghamella bertholletiae. The patient died despite appropriate antifungal management. A qPCR targeting Cunninghamella was developed a posteriori, and a retrospective analysis showed that a sample was positive more than 30 days before culture-based identification could be made.
Introduction
Mucormycosis is a frequently fatal invasive mold infection that has emerged in immunocompromised patients. Classic risk factors for developing mucormycosis are diabetes, systemic or local steroid use, immunosuppressive therapy for solid organ or stem cell transplantation, neutropenia, and deferoxamine therapy [1] . High doses of liposomal amphotericine B, posaconazole and surgery are the recommended therapeutic options [2] . However, mucormycosis is still associated with high mortality rates, specifically in hematological patients [3] .
Mucormycosis infections have the highest incidence in the eastern part of France and specifically in the FrancheComté region (0.33/10 5 /year) [4] . In 2013 we developed a qPCR targeting the most frequent genera of Mucorales (Rhizopus sp., Mucor sp., Lichtheimia sp., and Rhizomucor sp.). This new tool has contributed to accelerating diagnosis, allowing early initiation of effective antifungal therapy [5, 6] . Since then, other teams have reported similar conclusions using the same assay [7] or other systems of qPCR [8] .
We report here a case of mucormycosis due to Cunninghamella bertholletiae. This species is thought to be responsible for less than 1% of the reported mucormycosis cases and its considerable virulence has already been demonstrated [9] . This clinical case provided the opportunity to collect biological samples which have been used to develop and validate a specific qPCR targeting the Cunninghamella genus.
Case report
In 2016, a 61-year-old man was diagnosed with stage-B chronic lymphocytic leukemia. He underwent a fourth chemotherapy cycle of rituximab, fludarabine, and cyclosphosphamide (RFC) on 6th September (D0). On D21, he was admitted to the hematology unit for febrile aplasia. The fever persisted despite broad spectrum antibiotic therapy with piperacillin-tazobactam. Blood cultures were negative.
A chest, abdominal, and sinus computed tomography, performed at D23, was normal. A new chest tomography, performed at D33 showed a peripheral nodule and a condensation next to the right pulmonary hilus surrounded by less dense infiltration (Fig. 1a) . A probabilistic antifungal therapy with voriconazole, was initiated. Based on the imagery, the antifungal therapy was modified 72 h later for an association of posaconazole (400 mg twice per day) and liposomal amphotericin B (5 mg/kg); one week later, an increased dose of liposomal amphotericin B (10 mg/kg), still in association with posaconazole, was prescribed. Fungal biomarkers performed on sera (D33, D35, D36, D37, D38, D42, D45, and D49) and on broncho-alveolar lavage fluid (BALF) (D38), including galactomannan ELISA, Aspergillus fumigatus qPCR [10] and Mucorales qPCR (targeting Mucor sp, Rhizopus sp, Lichtheimia sp, and Rhizomucor sp) [5] , were negative. Direct examination and culture of the BALF were negative. At this point, a surgical resection was discussed but rejected because of the persistent aplasia, confirmed by deserted marrow on bone marrow aspiration smears. At D50, the patient was transferred to the intensive care unit because of respiratory failure, hypotension, and acidosis. Another computed chest tomography performed at D50 showed significant enlargement of the initial lesion with contralateral pleural effusion (Fig. 1b) , despite antifungal treatment.
Fungal biomarkers in sera (D51 and D58) and in BALF (D51) were still negative. At D65, an oro-tracheal intubation was performed with bronchoscopy and bronchial biopsy. Direct examination of the bronchial biopsy showed large hyphae compatible with Mucorales, and the culture was positive for Cunninghamella bertholettiae (Fig. 2) . The species identification was confirmed by ITS sequencing. A set of qPCR primers and hydrolyses probes were designed on the 18S rRNA gene to develop a Cuninghamella specific qPCR assay. Primers and probes were designed in a zone of high sequence homology between Cunninghamella species (Cunninghamella bertholletiae (AF113421.1), C. echinulata (AF157130.1), C. elegans (AF113422.1), and many mismatches with the other genera of Mucorales (Mucor a b Fig. 1 a Initial lesion at D33. b Expanded lesion at D50, after 13 days of antifungal treatment Fig. 2 Microscopic observation of Cunninghamella bertholletiae (obj ×100) racemosus (JF723685.2), Lichtheimia corymbifera (HM590655.1), and Rhizomucor pusillus (AF113434.1): forward primer TGTGGCTATGCAGCTGGTCA, reverse primer ACACATTCAGGCACGAAGGC and probe sequence (FAM)TCGGTCGGCGTGGTTCTCTGCCCA (TAMRA). Primer and probe specificity was validated by comparing their sequence with 18S rRNA sequences of all available filamentous fungi 18S sequences in the Genbank database (n = 71.900) using GASST software. DNA extracts of 8 sera and 2 BALF from the patient in this case study were retrospectively analysed by qPCR (Fig. 3) . Quantitative results were expressed using the quantification cycle (Cq) that marked the cycle at which fluorescence of the sample became significantly different from the baseline signal. Thus, the higher the Cq, the smaller the amount of DNA in the sample.
The patient's serum at D33 was the first tested and was positive with a Cq at 35. The sera tested later were all positive with Cq from 31 to 33. BALF at D51 was also positive with a Cq at 29. The BALF at D38 was negative. Etest MIC testing was performed for posaconazole (MIC 0.75 µg/ml), amphotericin B (MIC 1.5 µg/ml), and isavuconazole (MIC 0.5 µg/ml). The patient died at D75 after his fourth cycle of RFC chemotherapy. He never recovered from the aplasia induced by it.
Discussion
In the present clinical case, Mucorales qPCR was negative during patient monitoring, as the Cunnighamella genus was not targeted by the assay routinely performed in our Lab [5] . Identification of the species by culture of a tissue specimen was obtained only at D65 and a qPCR targeting C. bertholettiae was developed a posteriori. Seven sera from D33 to D58 and one BALF (D51) showed positive qPCR results, demonstrating that the species could have been identified more than 30 days sooner.
However, even if the species responsible for the infection was unknown, the patient did benefit from an appropriate antifungal treatment with a combination of liposomal amphotericin B and posaconazole. The absolute absence of any professional phagocytic cells is probably responsible for the expansion of the pulmonary lesions despite the antifungal treatment. A surgical resection was discussed repeatedly with a trained team, but the persistent neutropenia made it unworkable. The RFC chemotherapy regimen is currently recognized to significantly improve the response rate in chronic lymphocytic leukemia (CLL) and to prolong survival. However, its subsequent hematologic toxicity, with the persistence of grade 3 to 4 neutropenia, is a concern [11] .
Mucormycosis due to C. bertholletiae carries the poorest prognosis among all Mucorales infections, and this species is often refractory to systemic antifungals. The particular aggressiveness of this species is illustrated by the increase in circulating DNA load despite treatment with high doses of liposomal amphotericin B (Fig. 3) .
The Cunninghamella qPCR is a new tool that could be useful in a second wave of investigations when Aspergillus biomarkers and qPCR targeting the most frequent Mucorales genera prove to be negative whereas the imagery and context strongly support a fungal etiology. 
